Compare Abeona Therapeutics Inc (ABEO) vs Invesco Preferred ETF (PGX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Invesco Preferred ETF — how do they compare? Abeona Therapeutics Inc trades at $6.78 (market cap $373.32M), while Invesco Preferred ETF trades at $10.85. The key difference: Abeona Therapeutics Inc is trading nearer its 52-week high, Invesco Preferred ETF nearer its low. Which is the better fit depends on your goals.
| ABEO | PGX | |
|---|---|---|
Market Cap | $373.32M | — |
Sector | Health | — |
52-Week High | $7.23 | $11.87 |
52-Week Low | $4.17 | $10.82 |
Enterprise Value | $228.22M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
PGX trades at $10.88, showing no change over the past 24 hours. The technical outlook is bearish, with moving averages indicating a downtrend and oscillators neutral. The company recently announced the sale of its Golden Sidewalk Project to Kenorland Exploration Ltd. on June 18, 2026, as per GlobeNewsWire.
The outlook for PGX is cautious due to bearish technical signals and negative sentiment from financial media. Risks include poor returns and limited downside protection highlighted by Seeking Alpha on May 5, 2026. Investment opportunities may hinge on successful asset sales and future strategic shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Invesco Preferred ETF
The fund generally will invest at least 80% of its total assets in the components of the index. Strictly in accordance with its guidelines and mandated procedures, ICE Data Indices, LLC selects securities for the index, which is a market capitalization-weighted index designed to measure the performance of the fixed rate US dollar-denominated preferred securities market.
Read more on PGX →
